I-Mab
ANTI-CD73 ANTI-PD-L1 BISPECIFIC ANTIBODIES

Last updated:

Abstract:

Provided are bispecific antibodies capable of binding to human CD73 protein and human PD-L1 protein. These bispecific C antibodies are effective in treating cancer.

Status:
Application
Type:

Utility

Filling date:

25 Jul 2019

Issue date:

5 Nov 2020